ContraVir buys fellow antivirals developer Ciclofilin
Expanding its hepatitis B pipeline, ContraVir Pharmaceuticals Inc. is acquiring fellow antivirals developer Ciclofilin Pharmaceuticals Inc. (developing cyclophilin inhibitors) in exchange for the right to receive future earn-out payments in the form of up to $17mm in cash and up to 10% of ContraVir's issued and outstanding common stock.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.